ArticleJournal of thoracic disease2026
The value of serum biomarkers in the management of interstitial lung disease in patients with connective tissue disease: a protocol for an observational study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Three key points in managing interstitial lung disease (ILD) in patients with connective tissue disease (CTD) are: First, identifying risk markers or factors for ILD in CTD patients without ILD. Second, diagnosing ILD in CTD patients poses uncertainty about the diagnosis of ILD. Third, predicting treatment response and outcomes of CTD patients with ILD. The current management approaches largely depend on lung biopsy or high-resolution computed tomography (HRCT), both of which have limitations in terms of invasiveness and radiation exposure. Serum biomarkers offer the advantages of non-invasiveness, low cost, radiation-free exposure, and thus represent a potential tool for managing ILD. Methods: Here, we plan to conduct a prospective study to evaluate the value of serum biomarkers for predicting ILD risk, diagnosing ILD, assessing ILD prognosis, and predicting ILD treatment responsiveness in patients with CTD. We named this study "The value of serum biomarkers in diagnosing interstitial lung disease in connective tissue disease: a prospective diagnostic accuracy study" (VELD study). We will prospectively enroll CTD patients with uncertainty regarding ILD who visit the Departments of Rheumatology and Immunology at The Affiliated Hospital of Inner Mongolia Medical University between 2026 and 2028. Their serum specimens will be collected and stored at -80 ℃ for laboratory analyses, including biomarker screening and validation. The predictive and diagnostic values of serum biomarkers for ILD will be estimated using receiver operating characteristic (ROC) curve, decision curve analysis (DCA), logistic regression, net reclassification index (NRI), and integrated discrimination index (IDI). Discussion: The VELD study will provide a novel insight into the clinical role of serum biomarkers in the management of CTD-associated ILD. Trial Registration: chictr.org.cn (ChiCTR2600120197).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.